Today is the first day of the fifth exercise period for Bio-Works Technologies AB's warrants of series TO 2

Bio‑Works today opened the fifth exercise period (2–16 Jan 2026) for its TO 2 warrants issued in the August 2024 rights issue; each warrant entitles the holder to subscribe for one new share at SEK 1. Of 38,979,790 TO 2 issued, 20,265,542 have been exercised to date, leaving 18,714,248 outstanding; full exercise of the remainder would raise the share count by 18,714,248 to 116,939,370 and dilute capital and voting rights by ~16.0%. The release is procedural and provides prospectus/access information and regulatory disclosure (including FDI notification thresholds), with limited immediate market surprise but potential dilution risk for current holders.

Analysis

Market structure: The immediate mechanical effect is a potential issuance of 18,714,248 shares (16.0% dilution) if TO 2 holders exercise between 2–16 Jan 2026 at SEK 1, which would increase share count to 116,939,370 and inject SEK ~18.7m of cash into Bio-Works. That supply shock is front-loaded into a 15‑day window, creating short-term selling pressure if the stock trades meaningfully above SEK 1; conversely, if the stock is below ~SEK 1, warrants will expire worthless and upside is preserved.

Risk assessment: Tail risks include a failed exercise (holders partially exercise) resulting in uneven dilution and signaling weak holder conviction, or an FDI Act notification (>10% threshold) that blocks or delays strategic buyers — both could spike volatility. Timeline: expect price pressure days–weeks around Jan 2–16; medium term (1–6 months) the balance depends on whether SEK ~18.7m materially extends runway; long term hinges on commercial traction in bioprocessing.

Trade implications: Tactical trades should target the Jan exercise window: short/hedge if market price > SEK 1.10 (exercise economics clear), accumulate if price < SEK 0.95 (warrants likely to lapse). Options/vol trades: buy put spreads into late‑Jan/Feb to capture downside on exercise-induced supply; sell premium only if liquidity supports spreads.

Contrarian angles: Consensus will treat the exercise as pure dilution, but a full exercise delivers non‑dilutive cash per new share holder math and reduces warrant overhang beyond 2027 — once absorbed this can be positive. If market oversells into the exercise period, there is a 1–3 week mean‑reversion trade post‑settlement; monitor insider/major holder exercise behaviour for signal.

Key Decisions for Investors

• If BIOWKS trades > SEK 1.10 between 2–16 Jan 2026, establish a short position sized 2–4% NAV (or equivalent notional) with a stop at +5% and a target of 15–30% downside over 4–8 weeks to capture exercise-driven supply pressure.
• If BIOWKS trades < SEK 0.95 by 16 Jan 2026, build a long position sized 1–3% NAV, take profits if price recovers above SEK 1.20 within 3 months; rationale: warrants likely to lapse and downside limited by low exercise demand.
• Purchase Jan/Feb put spreads (buy ATM put and sell 10% OTM put) for a 30–60 day tenor sized to hedge ~50% of position exposure to capture volatility during/after the exercise window; keep max premium <2% NAV.
• Monitor filings under the Swedish FDI Act and any >10% ownership notifications in the next 30 days; if a strategic investor files, consider opportunistic 1–2% long position expecting takeover or consolidation speculation and a 10–20% re‑rating.